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Background: Emerging evidence suggests modulating the microbiota in the large bowel of patients with chronic
kidney disease (CKD) through pre- and/probiotic supplementation may inhibit the development of key nephrovascular
toxins. To date, quality intervention trials investigating this novel treatment in CKD are lacking. The aim of SYNERGY is to
assess the effectiveness of synbiotics (co-administration of pre- and probiotics) as a potential treatment targeting the
synthesis of uremic toxins, specifically, indoxyl sulphate (IS) and p-cresyl sulphate (PCS).
Methods/design: Thirty-seven patients with moderate to severe CKD (Stage IV and V, pre-dialysis) will be recruited
to a double-blind, placebo-controlled, randomised cross-over trial. Patients will be provided with synbiotic therapy or
placebo for 6 weeks, with a 4 week washout before cross-over. The primary outcome is serum IS, total and free
(unbound) concentrations, measured using ultra-performance liquid chromatography. Secondary outcomes include
serum PCS, total and free (unbound) concentrations; cardiovascular risk, measured by serum lipopolysaccharides, serum
trimethylamine-N-oxide (TMAO) and inflammation and oxidative stress markers; kidney damage, measured by 24 hour
proteinuria and albuminuria, estimated glomerular filtration rate and renal tubule damage (urinary kidney injury
molecule-1); patients’ self assessed quality of life; and gastrointestinal symptoms. In addition, the effects on the
community structure of the stool microbiota will be explored in a subset of patients to validate the mechanistic
rationale underpinning the synbiotic therapy.
Discussion: IS and PCS are two novel uremic toxins implicated in both cardiovascular disease (CVD) and
progression of CKD. Preliminary studies indicate that synbiotic therapy maybe a promising strategy when
considering a targeted, tolerable and cost-efficient therapy for lowering serum IS and PCS concentrations. This
trial will provide high quality ‘proof-of-concept’ data to elucidate both the efficacy of synbiotic therapy for lowering
the toxins and whether reductions in serum IS and PCS translate into clinical benefits. Considering the potential of
pre- and probiotics to not only shift toxin levels, but to also impede CVD and CKD progression, SYNERGY will
provide vital insight into the effectiveness of this innocuous nutritional therapy.
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In recent years, an appreciation for the role of the gut
microbiota in health and disease has gained momentum,
with microbial modulating therapies emerging in main-
stream medicine [1]. Within the discipline of Nephrol-
ogy, the evidence supporting the role of the kidney-gut
axis in uremia is building [2]. In fact, it is now clear that
the dysbiotic gut microbiotia observed in chronic kidney
disease (CKD) [3] produce key nephrovascular toxins,
indoxyl sulphate (IS) and p-cresyl sulphate (PCS) [4].
There is convincing evidence demonstrating dose-
dependent nephro- and cardiovascular toxicities of IS
and PCS in both in vitro and animal studies [5-7]. Fur-
ther, in the past decade there has been a surge of observa-
tional studies describing these toxins and their associations
with increased cardiovascular disease (CVD), kidney dis-
ease progression and all-cause mortality in the CKD popu-
lation [8-12]. This growing body of observational literature
warrants the need for more conclusive findings from inter-
vention studies to elucidate whether there is a causal role
of IS and PCS in the cardiorenal milieu, or whether they
are in fact biomarkers in vivo.
A number of therapeutic opportunities for targeting IS
and PCS have been proposed, including inhibition of co-
lonic bacterial biosynthesis (protein restriction and mi-
crobial modulating therapies), suppression of absorption
(oral adsorbents), augmentation of clearance (enhanced
dialysis) and modulation of cellular pathways (organic
anion transporters and antioxidants) [13]. Many of these
therapies remain limited to experimental studies, have
unfavourable side effects or a high cost burden prevent-
ing their translation to clinical research. In particular, oral
adsorbents have been extensively studied, with promisingTable 1 Mechanisms underpinning the scientific rationale for
production of indoxyl sulphate and p-cresyl sulphate
Prebiotics “A selectively fermented ingredient that allows specific changes,
both in the composition and/or activity in the gastrointestinal microflora
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inimprovements in both cardiovascular risk [14] and kidney
function [15] following reductions in serum IS. Nonethe-
less, a recent Phase III trial (n = 2035), Evaluating Preven-
tion of Progression In Chronic Kidney Disease (EPPIC),
demonstrated no difference between placebo and inter-
vention (AST-120) in CKD progression. Interestingly, post-
hoc analysis suggested poor compliance may have contrib-
uted to the negative outcome [16]. Microbial modulating
therapies, in the form of pre- and probiotcs, however,
present themselves as a promising treatment given their
low cost and innocuous nature. The potential benefit and
definition of pre- and probiotics are outlined in Table 1
[17,18]. These therapies have been summarised by a sys-
tematic review and meta analysis, which suggested an over-
all benefit for reducing the production of IS and PCS by
first altering the microbiota community in the large bowel
and thereby the metabolic activity and formation of these
metabolites within the colon [19]. However, this review
highlighted the body of evidence was weak due to poor
study design, suboptimal methodologic quality, significant
trial heterogeneity, and lack of scientific rationale for each
study’s supplement selection (probiotic strains, prebiotic
varieties and dosing). In addition, none of the trials evalu-
ated in this review were undertaken in the pre-dialysis
population where it may have the greatest therapeutic
benefit for delaying CKD progression, nor did they investi-
gate the effect of lowering the toxins on clinically relevant
markers and outcomes.
For these reasons, high quality studies are needed to
address 1) the efficacy of synbiotic therapy for reducing
IS and PCS and 2) whether such reduction in toxin con-
centrations is associated with clinical benefit. Answers to
these fundamental questions will ascertain the clinicalthe selection of the synbiotic formulation targeting the
lectively support the colonization of probiotics
crease the carbohydrate:nitrogen ratio in the colon favouring beneficial
ccharolytic vs. proteolytic fermentation
ecrease colonic pH (through short chain fatty acid production) thereby
pairing protein degradation with inactivation of pH sensitive proteases
crease the colonic transit time, thereby decreasing time for bacterial
roduction and intestinal absorption of indoxyl sulphate and p-cresyl
lphate
hance bacterial growth with increased uptake of the amino acids for
acterial biosynthesis and therefore less substrate for protein fermentation
cid and bile resistance to ensure survival through the upper
astrointestinal tract
ompetitive exclusion of indoxyl sulphate and p-cresyl sulphate producing
acteria (through competition for essential nutrients and luminal and
ithelial binding sites)
irect bacterial antagonism via inhibitory substance production (such as
iosurfactants, hydrogen peroxide, and bacteriocins)
munomodulation via immune cell activation resulting in indirect
hibition of pathogenic bacteria
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also provide new insight into how the microbiota may
be redirected to promote better clinical management of
CKD.Methods/design
Study aim
The aim of the SYNbiotics: Easing Renal failure by improv-
ing Gut microbiologY (SYNERGY) study is to investigate
the effects of synbiotics (co-administration of pre- and pro-
biotics) as a potential treatment for reducing IS and PCS
production in the CKD population. The primary hypothesis
is that synbiotic supplementation in patients with Stage IV
or V CKD (pre-dialysis) will be effective in reducing accu-
mulation of total and free (unbound) concentrations of IS.
The secondary hypotheses for SYNERGY include: a) reduc-
tion in total and free concentrations of PCS; b) reduction
in cardiovascular risk- measured by reduced endotoxemia,
trimethylamine-N-oxide (TMAO) and inflammatory and
oxidative stress markers; c) reduction in kidney damage-
measured by proteinuria and albuminuria and renal tubule
damage (urinary kidney injury molecule-1 (Kim-1)); d) im-
provement in quality of life (QOL); and e) improvement in
gastrointestinal (GI) symptoms.Study design
SYNERGY is a single-centre, double-blind, placebo-
controlled, randomised cross-over trial. Participants will
undergo a 2 week run-in period, followed by random-
isation to either synbiotic supplements or placebo for
6 weeks. Thereafter, participants will undergo a further
4 week washout period followed by crossover to the al-
ternative intervention (Figure 1). The 4 week washout
is considered sufficient for the pre-intervention micro-
biota to re-establish [19].Figure 1 SYNERGY study schema.Ethical considerations
Ethical approval has been granted through Metro South
Human Research Ethics Committee and the University
of Queensland Human Research Ethics Committee. Fur-
ther, Therapeutic Goods Administration has approved
the synbiotic supplements under the Clinical Trials No-
tification Scheme.Target population
The trial will recruit Stage IV-V non-dialyzed CKD pa-
tients. Inclusion criteria will include patients under the
care of a Nephrologist at the Princess Alexandra Hos-
pital with an estimated glomerular filtration rate (eGFR)
between 10-30 ml/min/1.73 m2, aged ≥18 years and able
to provide informed consent. Patients will be excluded if
they meet any of the following criteria: previous renal
transplant; receiving/or have received radiation to the
bowel or large bowel resection; consumed pre- or pro-
biotics or antibiotic therapy within 1 month of study
commencement; medically diagnosed irritable bowel
syndrome, Crohn’s disease or ulcerative colitis; non-English
speaking; likely to receive a transplant or progress to dialysis
within 6 months, as determined by treating physician; se-
verely malnourished (Subjective Global Assessment: C); or
having had a clinically significant change to their immuno-
suppressant dose within 6 months (determined by the
medical team). The latter criterion is to mitigate any
risk associated with severely immunocompromised pa-
tients, although increased risk even in the critically ill
is thought to be minimal [20].Dietary counselling
All participants will undergo face-to-face dietary edu-
cation and counseling with a qualified dietitian in line
with evidence-based guidelines [21], incorporating stand-
ard pre-dialysis education during the first week of run-in
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vided will be to target intake in line with current recom-
mendations [22], including protein intake at 0.8 g/kg/day
and to establish baseline dietary fibre intakes. In the week
following, and throughout the intervention, patients will
be encouraged to maintain stable protein and fibre in-
takes, with specific attention to maintaining the same
sources of these nutrients (ie. animal vs. plant protein and
soluble vs. insoluble fibre). Participants’ dietary intakes
and adherence to a stable diet during the study will be
assessed using a multi-method approach to optimize ac-
curacy of dietary intake estimates while minimizing pa-
tient burden. An open-ended, structured diet history
method will be used to establish usual intake at baseline
and the end of each intervention period. This method is
considered ideal for capturing usual intake over a prede-
fined period of time. In order to limit recall bias, a self-
administered diet history will be used based on a template
completed prior to the interview [23], and verified by the
same dietitian in a face-to-face interview. A 24 hr recall,
according to the US Department of Agriculture multiple
pass method [24], will be employed to assess the stability
of dietary intake throughout the study. This less time-
intensive dietary assessment method was chosen to limit
participant burden. Both diet assessment methods will
utilize food models to increase the accuracy of estimated
portions, particularly protein and fibre sources. Dietary
data will be entered into Food Works 7 (Xyris Software,
version 7.0.2915) using the Australian Food, Supplement
and Nutrient database (AUSNUT) 2007 (for key macro-
and micronutrients) and NZ Foodfiles 2010 (to quantify
soluble fibre and amino acids, not available in AUSNUT).
In addition, dietary protein intakes will be verified accord-
ing to the formula by Maroni et al. [25] using 24 hr urin-
ary urea nitrogen and body weight [26].Randomisation
Computer-generated randomisation of participants to
treatment order will be undertaken by an external statis-
tical consultant. This process of allocation will conceal the
randomisation order to researchers and participants. In
addition, the supplements will be packed off-site with a
generic label, supplement A or B, for the first and second
intervention, respectively.Pre- and probiotic intervention
The underlying rationale for selecting the bacterial strains
in the synbiotic formulation is the mechanistic inhibition
of bacterial production of IS and PCS (detailed in Table 1)
[27]. Importantly, the bacterial strains selected should
have limited, if at all, enzymatic capacity to produce IS
and/or PCS and ideally displace bacteria that do. On the
basis of these criteria, strains from the Lactobacillus andBifidobacteria genera present themselves as suitable candi-
dates for the purpose of this trial [28-30].
A strain from the Streptococcus thermophilus species
is also considered an important component in the syn-
biotic formulation due to its high urease capacity. In
fact, a previous study in the CKD population reported a
significant decrease in blood urea nitrogen (BUN) with
the inclusion of this species in the probiotic formula [31].
Hence, the probiotics in this study will contain strains
from the Lactobacillus, Bifidobacteria and Streptococcus
genera.
The prebiotic component will include high molecular
weight inulin (inulin HP), fructo-oligosaccarides (FOS)
and galacto-oligosaccarides (GOS), based on a number
of mechanistic benefits described in Table 1 [32,33]. In
addition, the literature suggests the production of IS and
PCS occurs in both the proximal and distal sections of
the colon. Therefore, in order to target and diminish the
colonic production of these toxins, a prebiotic product
that facilitates fermentation throughout the entire colon
is ideal. FOS and GOS both have small degrees of poly-
merisation (DP) (DP < 10) and therefore are completely
fermented in the proximal part of the colon. The
addition of inulin HP with a DP ranging from 10–60
may assist the extension of the fermentation to the distal
part of the colon [34].
In order to ensure the validity of the formulation, only
fibre varieties that have gone through the rigorous
process of attaining prebiotic status, as defined by Gib-
son et al. will be included [35].
Supplement dosing and duration
The synbiotic intervention will be a daily dose of 15 grams
of prebiotics, including a combination of 3 different types
of fibres, and the probiotic component will include 90 bil-
lion colony-forming units (CFU) from 9 different strains
across the Lactobacillus, Bifidobacteria and Streptococcus
genus. There is no consensus as yet on adequate dosing or
duration of synbiotics due to the diversity of GI survival
rates of probiotic strains and the different characteristics
of prebiotic varieties, such as their bifidogenic capacities
[33]. Nevertheless, the available evidence suggests that
there maybe be a threshold dose and duration required to
see a benefit for lowering IS and PCS production [19].
The dosing of pre- and probiotics used in SYNERGY is
based on previous successful trials [30,36,37]. However, in
order to minimise the side effects reported in previous
studies, such as flatulence and bloating [38], the synbiotics
will commence at half dose for the first 3 weeks.
The durations of most intervention studies in this area
have been ≤4 weeks, with one study demonstrating no
benefit comparing 4, 8 and 12 week intervention periods
[37]. The intervention period for SYNERGY is a 6 week
duration to allow time for dose escalation, minimise
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dependent and sustained benefit of the therapy.
Primary outcome
Serum indoxyl sulphate
Venous blood will be collected following an overnight
fast at 7 time points throughout the study, see Table 2.
Samples will be centrifuged at 3000 rpm for 10 mins be-
fore being stored at −80°C. Samples will be batched and
sent for analysis of serum concentration of IS, total and
free, using an ultra-performance liquid chromatography
(UPLC) and fluorescence detection method. This re-
cently validated method will allow for low limits of de-
tection down to 0.1 μmol/L and has been described in
detail by Pretorius et al. [39]. This method will also be
followed for PCS.
Participants will be provided with a standard evening
meal preceding their overnight fast before each blood
collection. This is a precautionary measure to minimise
any potential residual influences of the macronutrient




Plasma samples will be collected in endotoxin-free vials
following each intervention and stored at −80°C. Quanti-
fication of lipopolysaccharides will be undertaken using a
Limulus Amebocyte assay (Cambrex, Verviers, Belgium),
as described previously [40].Table 2 SYNERGY data collection schedule
Serum uremic toxins Indoxyl sulphate (free and total)
P-cresyl sulphate (free and total)
Cardiovascular risk Oxidative stress
Inflammation
Endotoxemia (lipopolysaccharide)
Kidney damage 24 hr albuminuria and protienuria
Kidney injury molecule-1
Estimated glomerular filtration rate
Dietary Diet history interview
24 hr recall
24 hr urinary urea nitrogen
Quality of life Short Form-36
Gastrointestinal symptoms Gastrointestinal symptom rating scale
Gut microbiota Fecal sample (optional)
Compliance Pill count
Dose escalationTrimethylamine-N-oxide
TMAO and its precursor, trimethylamine (TMA), will
be extracted from plasma with Acetonitrile-containing
labelled internal standards. The supernatant will then be
injected into a Waters UPLC system and separated under
reverse phase conditions. The column eluent will be intro-
duced into a Waters TQD Tandem Mass Spectrometer
and specific Multiple Reaction Monitoring (MRM) will be
carried out for each of the analytes.
Inflammation and oxidative stress
A panel of inflammatory markers, including interleukin-
6 (IL-6) and tumor necrosis factor-α (TNFα), will be
measured in serum samples before and after each inter-
vention using electrochemiluminescence immunoassay
techniques. Selection of these markers was based on
their regulatory association with Nuclear Factor-kappaB
(NF-kB) [41] and their association with IS and PCS in
the CKD population [42].
In addition, markers of lipid oxidation (total F2 iso-
prostanes) and endogenous antioxidant activity (glutathi-
one peroxidase (GPx)) will be measured to provide a
comprehensive assessment of potential pathways in-
volved in the toxicity of IS and PCS . These biomarkers
will be measured in plasma samples using validated
methods [43,44].
Kidney damage
SYNERGY will include kidney damage as a secondary
outcome using 24 hr urine samples (gold standard) forRun-in
Week −2
Intervention A & B
Baseline Mid point End point
Week 0 & 11 Week 3 & 14 Week 6 & 17
X X X X
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will be provided with bottles for collection and educated
on correct collection procedures in accordance with
standard protocol. Urinary total protein (pyrogallol red)
and urinary albumin (turbidimetric method based on
antibody-antigen complexes) will be measured in timed-
samples (mg/24 hrs) and cross-checked against creatin-
ine ratios (protein and albumin, respectively) on Beck-
man DxC800 general chemistry analyser (Beckman
Coulter, Brea, CA, USA) [46].
Kidney function using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) formula will also
be measured [22].
In addition, urinary Kim-1, a marker of kidney tubule
damage, will be measured from midstream urine collec-
tions before and after each intervention [47]. Samples
will be stored at −80°C, followed by analysis using a
commercially available sandwich ELISA according to the
manufacturer’s instructions (USCN Life Sciences, Wu-
han, PRC). Significant changes in Kim-1 have been
achieved in a 6 week dietary intervention study indicat-
ing the feasibility of Kim-1 as a sensitive marker in SYN-
ERGY [48].
Quality of life
QOL will be assessed in SYNERGY by the validated
Short Form-36 (SF-36), which has been used widely in
renal populations [49,50].
Gastrointestinal symptoms
Monitoring GI symptoms in SYNERGY has two pur-
poses, safety monitoring and hypothesis generation. The
validated Gastrointestinal Symptom Rating Scale (GSRS)
will be administered at baseline, mid-point (prior to dose
escalation), and the end of each intervention [51]. The
GSRS data will be presented as a total score and as di-
mension scores (reflux, pain, indigestion, constipation
and diarrhoea) [52].
Safety and adherence
All serious adverse events will be reported to the ethics
committee, whether deemed to be supplement related or
not. In addition, medical officers will cross-check all
blood and urine results during the study. Adherence to
supplements will be measured by pill count and powder
weight at both the mid point and end of each intervention.
Exploratory outcome
Gut microbiota
A microbial analysis will be an opt-in component to
SYNERGY. Fecal samples will be collected according to
standard procedures and stored at −80°C prior to batch
analysis pre and post each intervention. Microbial DNA
extraction will be performed using published methods[53] and the abundance of key probiotic bacteria mea-
sured by species-specific qPCR methodologies. These
specific bacteria as well as alpha- and beta-diversity
measures will be derived from barcoded amplicon librar-
ies of the V4 hypervariable region (517 F-803R) of the
prokaryote rrs genes present in each sample, using pro-
tocols similar to those described by Caporaso et al. [54].
The libraries will be sequenced using the Illumina MiSeq
platforms, and following demultiplexing and initial se-
quence quality control assessments, analyzed using the
Quantitative Insights Into Microbial Ecology (QIIME) pipe-
line (qiime.sourceforge.net) as described by Caporaso et al.
[55]. Enzymes relevant to the primary outcome of the study
(namely tryptophanase and 4-hydroxyphenylacetate de-
carboxylase, which catalyze the production of IS and PCS,
respectively) will also be measured. This is vital for proof of
concept exploration and to provide insight for refinement
of the synbiotic formulation.
Statistical analysis
Preliminary data from a cohort of CKD Stage IV-V (pre-
dialysis) patients recruited from the same Nephrology
department were used for power calculations. The mean
serum concentration of IS in this population was
14 μmol/L with a mean intra individual standard devi-
ation of 4 μmol/L between 3 measurements over a
6 week period (unpublished data from McMahon and
Campbell). With 1:1 randomisation, SYNERGY will re-
quire 24 participants to complete the study. This sample
size is based on a 30% reduction in IS levels; alpha of 5%
and power of 90%. Allowing for a 20% drop out and
using the adjustment factor 1/1(1-υ)2, a total of 37 par-
ticipants will be recruited. This magnitude of change is
related to a significant improvement in kidney function
[56]. Furthermore, a reduction in IS concentration of
this size has been achieved in previous probiotic inter-
vention studies and is therefore considered a realistic
target [57].
The primary analysis of IS concentrations will be
undertaken using an independent t-test with treatment
sequence allocation as the independent variable and the
difference between serum concentrations measured after
the first and second treatment as the dependent variable
[58]. Secondary analysis of the primary outcome will in-
clude mixed modelling to account for missing data and
to determine whether there is a dose dependent effect of
the synbiotics.
In addition to the widely used diversity metrics and
analysis tools available via QIIME, permutational multi-
variate analysis of variance (PERMANOVA) will be con-
ducted on the genus level operational taxonomic units
(OUT) tables to test the relationships between the stool
microbiome and the primary and secondary outcomes of
the study. Constrained ordination methods, such as
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be carried out [59].
Previous studies in pre-dialysis populations suggest a
high incidence of antibiotic prescription secondary to
high comorbidity burden, susceptibility to urinary tract
infections, and prophylactic use for surgical procedures.
Because this is a proof-of-concept study and the use of
antibiotics may confound the mechanisms underpinning
the synbiotic therapy, sensitivity analyses will be under-
taken including and excluding patients prescribed antibi-
otics during either intervention arm. In addition, further
analysis will be undertaken to assess whether there is a
treatment order effect. The null hypothesis will be
rejected at the 0.05 level. The statistical analyses will be
performed using Stata (version 12, 2012, Statacorp, Col-
lege Station, TX).
Discussion
This double-blind placebo-controlled randomised cross-
over trial has been designed to provide evidence in order
to better determine whether synbiotic therapy can re-
duce serum concentrations of IS and PCS and in turn
improve clinical outcomes in CKD. In addition to over-
coming suboptimal study design and methodological
limitations of previous studies, SYNERGY aims to ad-
dress the translation of the inflammatory and oxidative
mechanisms that are thought to underpin the toxicities
of IS and PCS contributing to the high prevalence of
premature CVD observed in CKD [60]. More explicitly,
in vitro studies suggest the pathogenic actions of IS and
PCS stem from the induction of reactive oxygen species
(ROS), which activate the NF-kB pathway, resulting in
both oxidative stress and pro-inflammatory cytokine
production [61,62]. Furthermore, treatment with antioxi-
dants and NF-kB inhibitors dose-dependently inhibit the
fibrotic and oxidative effects of IS and PCS [5,14,63].
SYNERGY will be one of the first intervention studies to
investigate the translation of these mechanisms in the
CKD population.
There are a number of other mechanistically plausible
benefits of synbiotic therapy in CKD, independent of the
effect on IS and PCS reduction, that will be explored in
SYNERGY, specifically, endotoxemia, TMAO, QOL, GI
symptoms and microbiota form and function.
Endotoxemia, a marker of impaired intestinal barrier
function, has been identified across the full spectrum of
CKD, with levels of circulating endotoxins increasing with
declining kidney function [64]. Some of the factors con-
tributing to this in CKD include the high prevalence of
small bowel bacterial overgrowth [65], increased mem-
brane permeability secondary to chronic low grade inflam-
mation [66], and gut edema secondary to fluid overload
and ischemic intestinal injury particularly in the dialysis
population [64]. The potential benefit of probiotics onintestinal lining integrity has gained recognition recently,
with studies in liver disease patients demonstrating a sig-
nificant reduction in endotoxin levels following synbiotic
therapy [67,68]. Some of the mechanisms proposed in-
clude enhanced epithelial barrier function via induction
of mucin production, blocking of epithelial binding re-
ceptors, and strengthening of epithelial tight junctions
through increased expression of proteins [69]. It is there-
fore conceivable that endotoxemia may improve following
synbiotic therapy in CKD.
Like IS and PCS, TMAO is a derivative of colonic bac-
terial fermentation and has recently been identified as a
proatherogenic risk factor [70]. Emerging research has
demonstrated that TMAO not only promotes athero-
sclerosis in mice, but raised levels are associated with
major adverse cardiac events in humans (n = 2595) [71].
Despite this link between TMAO and atherosclerosis
only recently surfacing, increased levels of TMAO in
end stage kidney disease and its amenability to gut mi-
crobial manipulation has been recognised for decades
[72]. Therefore a decrease in serum TMAO is an attract-
ive prospect following synbiotic therapy.
QOL in CKD patients is often compromised with levels
of depression associated with declining kidney function
[73]. There is a growing body of evidence substantiating
the microbiota-gut-brain axis, linking alterations in the
gut microbiota with depression [74]. Further, animal stud-
ies have demonstrated that both pre- [75] and probiotics
[76] have psychotropic effects, suggesting improvements
in QOL following synbiotic therapy is a credible hypoth-
esis. In fact, this theory has been supported in a rando-
mised controlled cross-over study where a cohort of 46
participants with CKD stage 3–4 were reported to have a
significant improvement in their QOL following probiotic
therapy [77].
GI symptoms are increased in CKD compared to the
general population. Furthermore, an observational study
comparing the CKD population with the general popula-
tion highlighted significantly worse GI symptom across
5 GI domains (pain, indigestion, constipation, diarrhoea
and eating dysfunction) using the GSRS tool [52]. Given
the reported benefits of pre- and/or probiotics span across
these 5 GI domains [78], GI symptom improvement pre-
sents itself as another promising outcome measure in
SYNERGY.
The microbiota analysis in this study should help
evaluate whether the probiotic strains per se, or other
alterations in the microbiota of the large bowel, might
contribute to these outcomes.
Lastly, the role of diet in serum IS and PCS concen-
trations is well documented, yet monitoring dietary in-
take has been a limitation of studies to date [79]. One
of the key strengths of SYNERGY that will enhance the
rigour of this trial is the multi-method approach to
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study.
In summary, considering the potential for synbiotics to
not only shift toxin levels, but to also impact on CVD
and CKD outcomes, there is a need for well designed,
intervention studies to establish the effectiveness of this
innocuous, low cost therapy. The SYNERGY study aims
to provide proof-of-concept data to elucidate whether al-
tering the microbiota in the CKD population is likely to
be effective, tolerable and can impede the processes as-
sociated with CVD and CKD progression.
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